IDENTITY: InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2
Study Details
Study Description
Brief Summary
The purpose of the study is to obtain and centralize data about cancer prevention strategies in women with a germline deleterious mutation in BRCA1-2 with or without a history of breast cancer in Italy
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Women who carry a deleterious mutation in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) have an elevated lifetime risk of developing breast and ovarian cancer, estimated at up to 7 and 25 times that of the average risk population, respectively. By the age of 80 years, the estimated cumulative risk of breast cancer is about 70% for BRCA1/2 mutation carriers, while the cumulative ovarian cancer risk is about 40% for BRCA1 and 20% for BRCA2 carriers. Thus, BRCA1/2 mutation carriers are advised to consider different risk-reducing strategies, including surveillance (breast self-examination, clinical breast examination, screening using mammography, ultrasound and breast magnetic resonance imaging), chemoprevention and prophylactic surgery (prophylactic mastectomy and/or salpingo-oophorectomy). Prospective cohort studies demonstrate that risk-reducing mastectomy is associated with 90% or more decreased risk of breast cancer. Unfortunately, it is difficult to quantify its effect on overall mortality since no randomized studies have compared risk-reducing mastectomy with enhanced screening, risk-reducing salpingo oophorectomy or prophylactic treatment. Additionally, prophylactic mastectomy is an invasive intervention associated with a substantial complication rate and psychological distress, changes in body image and sexual function. Therefore, as a preventive measure, risk-reducing mastectomy should be discussed on a case-by case basis, after proper counseling regarding benefits, limitations, risks of surgical complications and psychosocial impact. Conversely, risk-reducing salpingo oophorectomy is strongly recommended for women with mutations in BRCA1 (between ages 35 and 40 years) and BRCA2 (between ages 40 and 45 years) after completion of childbearing desire, for a significant reduction in ovarian cancer incidence and all-cause mortality. In the absence of solid evidences coming from randomized clinical trials, the aim of the present study is to collect and centralize real-world data on cancer prevention strategies (prophylactic surgery, prophylactic therapies, active surveillance) and oncologic treatments of women with a deleterious mutation in BRCA1-2 with or without a diagnosis of breast cancer in Italy. By collecting and analyzing these data, the IDENTITY study aims to obtain a faithful representation of the practices related to oncological surveillance in the group of patients analyzed.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cohort A (Retrospective) all consecutive women with a germline deleterious mutation in BRCA1-2 admitted to the participant Center since 1st of January 2010 until site activation will be enrolled |
|
| Cohort B (Prospective): all consecutive women with a germline deleterious mutation in BRCA1-2 admitted to the participant Center since site activation until September 2025 will be enrolled |
Outcome Measures
Primary Outcome Measures
- To obtain and centralize data about cancer prevention strategies in women with a germline deleterious mutation in BRCA1-2 with or without a history of breast cancer in Italy [10 years since enrolment]
To obtain and centralize data about cancer prevention strategies in women with a germline deleterious mutation in BRCA1-2 with or without a history of breast cancer in Italy
Secondary Outcome Measures
- To evaluate the clinico-radiological follow-up (type and frequency) of women with a germline deleterious mutation in BRCA1-2 with or without a history of early breast cancer [10 years since enrolment]
To evaluate the clinico-radiological follow-up (type and frequency) of women with a germline deleterious mutation in BRCA1-2 with or without a history of early breast cancer
- To evaluate the treatment of early and/or advanced breast cancer in women with a germline deleterious mutation in BRCA1-2 [10 years since enrolment]
To evaluate the treatment of early and/or advanced breast cancer in women with a germline deleterious mutation in BRCA1-2
- To evaluate disease-free survival and/or progression-free survival and overall survival of women with a germline deleterious mutation in BRCA1-2 treated for early and/or advanced breast cancer [10 years since enrolment]
To evaluate disease-free survival and/or progression-free survival and overall survival of women with a germline deleterious mutation in BRCA1-2 treated for early and/or advanced breast cancer
Eligibility Criteria
Criteria
Inclusion Criteria:
Cohort A (Retrospective):
-
Female sex
-
Age ≥ 18 years
-
Signed informed consent
-
Documented germline deleterious mutation in BRCA1 and/or BRCA2 in people with: i) No history of cancer ii) Radically treated breast cancer iii) Stage IV breast cancer diagnosed after BRCA1-2 mutation detection
-
Admission to the participating Center since 1st of January 2010, prior to site activation
Cohort B (Prospective):
-
Female sex
-
Age ≥ 18 years
-
Signed informed consent
-
Documented germline deleterious mutation in BRCA1 and/or BRCA2 in people with: i) No history of cancer ii) Radically treated breast cancer iii) Stage IV breast cancer diagnosed after BRCA1-2 mutation detection
-
Admission to the participating Center after site activation
Exclusion Criteria:
Cohort A/B (Retrospective/Prospective):
- Other malignancies diagnosed within five years prior to BRCA1-2 mutation detection, except for:
-
ovarian cancer stage I-II
-
basal or squamous cell carcinoma of the skin
-
melanoma in situ
-
CIS of the cervix
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centro di Riferimento Oncologico - Aviano | Aviano | Pordenone | Italy | 33081 |
| 2 | IRCCS AOU San Martino, IST Genova | Genova | Italy | ||
| 3 | Azienda Ospedaliera Papardo | Messina | Italy | ||
| 4 | ASST Ovest Milanese | Milano | Italy | ||
| 5 | Azienda ospedaliera Universitaria di Modena | Modena | Italy | ||
| 6 | Università degli studi di Napoli Federico II | Napoli | Italy | ||
| 7 | Azienda AUSL IRCCS - Reggio Emilia | Reggio Emilia | Italy | ||
| 8 | ASL Roma 1, Santo Spirito | Roma | Italy | ||
| 9 | IFO - Istituto Regina Elena (Oncologia medica 2) | Roma | Italy | ||
| 10 | Policlinico Universitario Gemelli | Roma | Italy | ||
| 11 | Città della salute Torino, PO S. Anna | Torino | Italy | ||
| 12 | ASU FC Azienda Sanitaria Universitaria Friuli Centrale | Udine | Italy |
Sponsors and Collaborators
- Centro di Riferimento Oncologico - Aviano
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CRO-2019-33